The Lynx Group
Cholangiocarcinoma News

FOENIX-CCA2 Quality-of-Life Data for Futibatinib-Treated Patients with Intrahepatic CCA and FGFR2 Fusions/Rearrangements

2021 Year in Review: Cholangiocarcinoma — December 17, 2021

Findings of patient-reported outcomes from the phase 2 FOENIX-CCA2 study indicate that quality-of-life data and overall health status were maintained among futibatinib-treated patients with advanced intrahepatic CCA.

The pivotal phase 2 FOENIX-CCA2 trial (ClinicalTrials.gov Identifier: NCT02052778) evaluated the investigational FGFR1-4 inhibitor futibatinib in patients with intrahepatic cholangiocarcinoma (iCCA) who harbored FGFR2 fusions/rearrangements. Results for the preplanned analysis of patient-reported outcomes (PROs) to evaluate health-related quality of life and health status during futibatinib treatment were reported at the 2021 American Society of Clinical Oncology Annual Meeting.

The FOENIX-CCA2 study enrolled patients from 36 international sites with unresectable/metastatic iCCA with an FGFR2 fusion/rearrangement and progressive disease (PD) after ≥1 prior treatments. Eligible patients received oral futibatinib 20 mg once daily until PD or intolerability. Data cutoff was October 1, 2020. PROs, which were assessed during futibatinib treatment as a secondary objective, were collected at screening, cycles 2 and 4, every 3 cycles thereafter, and end of treatment. PRO data were evaluated up to cycle 13 (the last visit before data were missing for >50% of the PRO population), which corresponded to 9.0 months on treatment. PRO measures included EORTC QLQ-C30 (1 global health, 5 functional, 9 symptom scales); EuroQoL 5-dimensional instrument (EQ-5D-3L); and EQ visual analog scale (VAS).

Of the total enrolled population (n = 103), 92 participants had PRO completion data at baseline and a minimum of 1 follow-up assessment; 48 patients had PRO data at cycle 13. The median age of the PRO population was 58 years; 56.5% were female; 52.2% had an European Cooperative Oncology Group performance status score of 1. Mean time since diagnosis was 17.8 months, and mean time since most recent recurrence/relapse was 2.9 months.

During the PRO assessment period (from baseline to cycle 13), mean EORTC QLQ-C30 global health status scores and functional scales were maintained, with no clinically meaningful (≥10-point) changes in individual functional measures. In terms of individual symptom measures, EORTC QLQ-C30 scores were also mostly stable from baseline through cycle 13; only constipation showed an average of 10.0-point worsening at only cycle 4. Mean EQ VAS scores were maintained from baseline to cycle 13, with values maintained within the population norm range from across 20 countries. Mean EQ-5D-3L status change from baseline to cycle 13 remained unchanged or improved for the majority of patients across all dimensions. A large proportion of patients showed improvement in pain/discomfort and anxiety/depression scores, and worsening in mobility, usual activities, and self-care dimensions.

Based on these PRO results of the phase 2 FOENIX-CCA2 trial, the researchers concluded that quality-of-life data related to physical, cognitive, and emotional functioning, as well as overall health status, were maintained among futibatinib-treated patients with advanced iCCA.

Source: Valle JW, Hollebecque A, Furuse J, et al. FOENIX-CCA2 quality of life data for futibatinib-treated intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions/rearrangements. J Clin Oncol. 2021;39(suppl_15):4097-4097.

Related Items

Phase 1 Results of Gunagratinib in Patients with Advanced Solid Tumors Harboring FGFR Pathway Alterations
2021 Year in Review: Cholangiocarcinoma
A phase 1/2a, first-in-human clinical study demonstrated that the highly selective, irreversible pan-FGFR inhibitor gunagratinib was safe and well-tolerated in patients with advanced solid tumors, including CCA.
Prognostic Value of FGFR2 Alterations in Patients Receiving Systemic Chemotherapy for Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis indicated the prognostic value of FGFR2 fusions/rearrangements in patients with intrahepatic CCA receiving systemic chemotherapy, which warrants additional study.
FGFR2 Fusion and/or Rearrangement Profiling in Chinese Patients with Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Epidemiologic data assessed the incidence rate of FGFR2 gene fusion or rearrangement in Chinese patients with intrahepatic CCA, including those with heterogeneous FGFR2 partner genes.
A Comprehensive Genomic and Immune Profiling Study of IDH1- and IDH2-Driven Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A comprehensive genomic and immune characterization of IDH-mutated and wild-type intrahepatic CCA revealed significant differences in genetic alterations.
Characteristics of IDH Mutations in Bile Duct Carcinoma in a Chinese Population
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis in a large Chinese patient cohort with bile duct carcinoma indicated that activating IDH1/2 mutations occurred at a lower rate compared with that previously reported in the global population.
Silmitasertib (CX-4945) plus Gemcitabine and Cisplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic CCA
2021 Year in Review: Cholangiocarcinoma
Preliminary evidence suggests that combination treatment with silmitasertib plus gemcitabine/cisplatin as first-line therapy has promising efficacy and a favorable safety profile in patients with locally advanced or metastatic CCA.
Targeted Therapies in CCA: Assessment of US Oncologist Practice Patterns
2021 Year in Review: Cholangiocarcinoma
Findings from a clinical practice assessment identified gaps in knowledge, competence, and confidence regarding testing and the use of targeted therapies in patients with unresectable CCA, underscoring the important role of education in overcoming these gaps.
First-Line Toripalimab plus Lenvatinib in Combination with GemOx Chemotherapy for Advanced Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Results of a phase 2 study indicate that toripalimab and lenvatinib in combination with GemOx chemotherapy provide antitumor activity and reasonable tolerability in patients with advanced intrahepatic CCA.
Comparative Landscape of Actionable Somatic Alterations in Advanced CCA from Circulating Tumor and Tissue-Based DNA Profiling
2021 Year in Review: Cholangiocarcinoma
Findings from a retrospective analysis support the use of both tissue and liquid biopsy biomarker testing to guide therapy selection in patients with advanced CCA, particularly when tissue may not be readily available.
Tibsovo (Ivosidenib) FDA Approved for Advanced or Metastatic Cholangiocarcinoma and IDH1 Mutation
By Loretta Fala
2021 Year in Review: Cholangiocarcinoma
Cholangiocarcinoma (CCA) is an aggressive cancer of the bile duct that forms inside the liver (ie, intrahepatic) or outside the liver (ie, extrahepatic, including perihilar and distal tumors). Individuals with colitis or certain liver diseases may have an increased risk for CCA. Although the precise incidence of CCA is unknown, an estimated 8000 new cases of CCA are diagnosed annually in the United States. It is likely, however, that this number is higher, because CCA is difficult to diagnose and may be misclassified at times.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: